Jump to main content
Jump to site search


A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints

Author affiliations

Abstract

We reported that (−)-epicatechin can stimulate mitochondria biogenesis and improve metabolism. However, preliminary studies indicate that the (+) stereoisomer form may be more potent. We evaluated in a preliminary manner, the pharmacokinetics (PK) and initial safety analysis of (+)-epicatechin ((+)-Epi) in healthy and pre-diabetic subjects. Using a mouse model of diet-induced obesity and insulin resistance, we also evaluated the metabolic effects of (+)-Epi vs. (+)-catechin (Cat) to determine class effects. In the Phase I PK study, subjects were provided a single incremental oral dose of (+)-Epi (10, 30 or 100 mg). For the PD study, subjects were provided a single 30 mg dose per day for 7 days. Blood samples were collected and safety measures were performed. Incremental doses of (+)-Epi increase the half-life of blood metabolites from 1.2–4.9 h. The compound was well tolerated and no adverse effects were reported. Seven day dosing of pre-diabetic subjects led to tendencies for reductions in circulating levels of tumor necrosis factor-α and monocyte chemoattractant protein-1, which returned to baseline by 7 days after treatment. In animals, 2 weeks of oral dosing (0.003, 0.01, 0.03, 0.1 and 0.3 mg kg−1 day−1) dose dependently improved metabolism-related endpoints (weight gain, glucose, cholesterol, triglyceride, with thresholds as low as 0.01 mg kg−1 day−1). Cat yielded no effects at 0.1 mg kg−1 day−1. Results indicate that (+)-Epi evidences a favorable PK and safety profile. Using a pre-clinical model, the compound positively modulates metabolism, which may link to mitochondrial effects. Effects are not due to general antioxidant actions, as Cat yielded no effects.

Graphical abstract: A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints

Back to tab navigation

Supplementary files

Publication details

The article was received on 11 Jul 2017, accepted on 14 Nov 2017 and first published on 15 Nov 2017


Article type: Paper
DOI: 10.1039/C7FO01028A
Citation: Food Funct., 2018, Advance Article
  •   Request permissions

    A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints

    A. Moreno-Ulloa, N. Nájera-García, M. Hernández, I. Ramírez-Sánchez, P. R. Taub, Y. Su, E. Beltrán-Partida, G. Ceballos, S. Dugar, G. Schreiner, B. M. Best, T. P. Ciaraldi, R. R. Henry and F. Villarreal, Food Funct., 2018, Advance Article , DOI: 10.1039/C7FO01028A

Search articles by author

Spotlight

Advertisements